Tim Nichols

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 269 citations · Full text

Medicine, Oncology, Pharmacology +15

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Alessandra Blasina, Jill Hallin, Enhong Chen et al. · Molecular Cancer Therapeutics · 2008 · 226 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

Cathy C. Zhang, Zhengming Yan, Wenlin Li et al. · Clinical Cancer Research · 2011 · 76 citations

Medicine, Nuclear Medicine, Oncology +17

Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction

Gina M. Yanochko, Allison Vitsky, Jonathan R. Heyen et al. · Toxicological Sciences · 2013 · 71 citations

Medicine, Cardiology, Pharmacology +15

Synthetic αVβ3 Antagonists Inhibit Insulin-Like Growth Factor-I-Stimulated Smooth Muscle Cell Migration and Replication1

David R. Clemmons, Gayle D. Horvitz, Wayne Engleman et al. · Endocrinology · 1999 · 51 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +15